SELLAS Life Sciences AML Trial Readout Amid Probe
SELLAS Life Sciences Group, a 13-person biotech with a $2.02 billion valuation entirely dependent on its Phase 3 AML trial, is now facing a securities investigation into its trial disclosure practices
SELLAS AML Trial Nears Readout Amid Disclosure Probe
NEW YORK, October 19 —
The same AML survival data that drove SELLAS Life Sciences Group, Inc. (SLS) shares to record first-half 2026 highs has drawn a securities probe. Pomerantz law firm opened an investigation into the company's trial disclosure practices on October 17, just as reports of new interim data circulated and an imminent Phase 3 readout drew institutional and retail attention alike.
- Analyst consensus price target: $32.50, implying 225% upside from $9.98; cash on hand $140 million, zero long-term debt.
- 27.4% of the float is sold short, more than one in four public shares betting against the rally.
- Vanguard Capital disclosed a 5.19% stake; institutional ownership stands at 37%, insider ownership at 0.9%.
A $2 Billion Bet on One Trial
SELLAS Life Sciences Group, with 13 employees and no commercial revenue, carries a $2.02 billion valuation resting entirely on its clinical pipeline. The lead compound, galinpepimut-S (GPS), is a peptide immunotherapy targeting the Wilms Tumor 1 antigen expressed across multiple cancer types; it is being evaluated in a Phase 3 AML trial and, via a collaboration with Merck & Co., in combination with Keytruda across up to five indications. That Phase 3 readout, described as imminent this week, is the entire investable thesis for a company burning $28 million annually with no revenue. Current financials are tracked at the SELLAS stock page.
The Catch
Pomerantz, which specializes in securities class-action investigations, opened a probe into SELLAS's trial disclosure practices on October 17, one day before reports of new AML survival data circulated among retail participants who characterized it as significant. The sequence matters: if interim results were selectively distributed ahead of the announcement, not all market participants would have received equal access to the same information. The short book adds to the picture: 27.4% of the float is sold short, placing more than one in four public shares against both the Vanguard stake and the analyst price consensus.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| SLS | $2.0B | n/a | +396.5% |
| GLSI | $214M | n/a | +56.8% |
| IMMP | $24M | n/a | -92.2% |
| VTVT | $105M | n/a | +28.8% |
| IBRX | $9.7B | n/a | +274.7% |
| CAPR | $390M | n/a | +4.8% |
What the Readout Settles
Vanguard Capital's reported 5.19% stake aligns with the $140 million cash cushion and zero long-term debt, giving the company runway to reach the readout without a near-term dilutive raise. The Phase 3 AML result is the decisive test: survival data has reportedly already been previewed informally, so the formal announcement will resolve not just the scientific question but the disclosure one, determining whether that early access reflects legitimate conviction or regulatory exposure. For context on one framework for valuing GPS, see the full DCF model and price target →.
Current fundamentals, valuation and filing history for SELLAS Life Sciences Group, Inc. (SLS) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What is SELLAS Life Sciences valuation based on?
SELLAS is a 13-employee biotech company with a $2.02 billion valuation and no commercial revenue. Its entire investable thesis rests on galinpepimut-S (GPS), a peptide immunotherapy targeting the Wilms Tumor 1 antigen being evaluated in a Phase 3 AML trial and in a collaboration with Merck Co. for combination with Keytruda.
Why is SELLAS under a securities investigation?
Pomerantz law firm opened a probe on October 17 into SELLAS's trial disclosure practices. The investigation was triggered by reports that new interim AML survival data circulated among retail participants before a formal announcement, raising questions about whether all market participants received equal information access.
When is the SELLAS Phase 3 AML trial readout expected?
SELLAS has described its Phase 3 AML trial readout as imminent this week. The company has reportedly already previewed interim survival data informally, so the formal announcement will resolve both the scientific outcome and the disclosure question simultaneously.
What is the short interest in SELLAS stock?
27.4% of SELLAS's public float is sold short, placing more than one in four shares in opposition to the analyst price consensus. This substantial short position compounds concerns around trial disclosure timing and regulatory outcomes.
What is the analyst price target for SELLAS?
Analyst consensus price target for SELLAS is $32.50, implying 225% upside from the current price of $9.98. The company has $140 million in cash and zero long-term debt, providing runway to reach the trial readout without a dilutive capital raise.
SELLAS Life Sciences shares have surged to first-half 2026 highs on mounting excitement over an imminent Phase 3 AML trial readout — but Pomerantz law firm has simultaneously opened a probe into how the company disclosed its trial data, injecting legal risk directly into the thesis driving the rally.